AUBRAI

Aubrai by Bio Price Today & AI Analysis

AUBRAI
Base·AI Analysis
Analysis as of May 2, 2026

$1.17

+0.30%24h
LiveContract:0x9d56c29e820dd13b0580b185d0e0dc301d27581dChain:BaseHolders:3.0KMarket cap:$2.33MLiquidity:$37.95K

More tokens on Base

G

GD

Golden Dragon

$0.0035600.9%
MC $356.0K
PMFI

PMFI

PMFI

$0.0634641.2%
MC $34.6K
PRIME

PRIME

Prime

$0.22190.1%
MC $391.1K
BOOMER

BOOMER

Boomer

$0.0003172.0%
MC $317.4K
HermesOS

HermesOS

Hermes OS

$0.0696211.9%
MC $96.2K
GOOGLc

GOOGLc

Alphabet Inc.

$343.521.5%
MC $2.18M

Advanced charting powered by TradingView

Continue in chat

Ask Unhosted AI about AUBRAI

What's Twitter saying?

Sentiment, KOL mentions, top tweets

Whale activity

Who is accumulating or distributing

What are the risks?

Red flags, security, concentration

Should I buy?

Bull case, bear case, entry / exit

Movement since reportreport from May 2, 2026, 12:00 PM UTC
Market Cap

$4.04M

24h Volume

$0.00

Liquidity

—

FDV

—

Holders

2.8K

24HLoading trading activity…

Holder Insights

Live

Total holders

—

AI Executive Summary

Aubrai is a novel decentralized AI agent token focused on longevity science, co-developed by VitaDAO and BIO with backing from Dr. Aubrey de Grey's research. The token operates at a $4.04M market cap with 2M total supply and represents a unique intersection of AI, biotech, and decentralized science. However, the token exhibits extreme holder concentration (88% in top 10) and virtually no retail participation, creating significant structural risks despite its innovative positioning and institutional credibility.

Figures cited above are from the market snapshot taken when this analysis ran — May 2, 2026, 12:00 PM UTC. Live values may differ; the key facts at the top of the page are current.

Risk: high
Sentiment: neutral
First decentralized scientific AI agent specifically designed for longevity research with access to proprietary lab data
Institutional backing from established DeSci platforms (VitaDAO, BIO) and Dr. Aubrey de Grey's research network
Tangible scientific milestone (RMR2 project) with potential paradigm-shifting implications for aging research

Aubrai by Bio AI Price Analysis

Medium Confidence
Short-Term24h-7d
Neutral

With 88% of supply concentrated in the top 10 holders and only 0.28% holder growth in 24 hours, short-term price action is likely to remain range-bound with low volatility. The token shows minimal retail participation (0% of supply), suggesting limited organic buying pressure. Recent holder growth of 1.5% over 7 days indicates gradual but modest accumulation interest.

Medium-Term30d-90d
Bullish

Medium-term outlook is cautiously bullish if RMR2 project milestones are achieved and community adoption increases. The token's unique positioning in longevity science and AI agents provides differentiation, but success heavily depends on scientific validation and ecosystem expansion. Holder growth of 4.9% over 30 days suggests emerging interest, though concentration risk remains the primary constraint.

Bullish Factors
  • +Unique positioning as first decentralized scientific AI agent in longevity research - no direct competitors identified
  • +Strong institutional backing through VitaDAO and BIO partnerships, providing credibility and resources
  • +Holder growth of 4.9% over 30 days indicates emerging organic interest despite concentration
  • +Verified smart contract with 68/100 security score reduces technical risk
  • +RMR2 project represents potential 'AlphaFold moment' for aging research with significant upside if successful
  • +Fully diluted valuation of $5.85M is modest for a project with institutional backing and scientific focus
Bearish Factors
  • -Extreme concentration risk: 88% of supply held by top 10 addresses creates severe dump risk and price manipulation vulnerability
  • -Zero retail holder participation (0% of supply) indicates lack of grassroots adoption and community engagement
  • -Only 2,810 total holders for a token with institutional backing suggests limited market penetration
  • -Minimal 24-hour holder growth (0.28%) indicates weak short-term momentum despite medium-term growth
  • -Liquidity data not provided - potential shallow liquidity could cause significant slippage on larger trades
  • -Scientific project success is uncertain; RMR2 results could take years and may not validate the hypothesis
  • -Regulatory uncertainty around AI agents and biotech tokenization could impact adoption

Disclaimer: This AI-generated prediction is for informational purposes only and does not constitute financial advice. Cryptocurrency investments are highly volatile. Always conduct your own research.

Token Info

ChainBase
Contract0x9d56...581d
Total Supply—
Decimals—

Key Risks

•Extreme concentration risk: 88% supply in top 10 holders creates severe vulnerability to coordinated selling, price manipulation, and single-address liquidation events
•Scientific execution risk: RMR2 project success is uncertain and could take years; failure would undermine project credibility and token value
•Liquidity risk: Unknown liquidity depth combined with concentration suggests large trades could face severe slippage; retail investors may struggle to accumulate positions
•Regulatory risk: Emerging regulatory frameworks for AI agents and biotech tokenization could impact token utility or project viability

Trading Insight

neutral

Trading sentiment is neutral with slight bullish bias from holder growth, but severely constrained by extreme concentration and lack of retail participation. The 1.5% weekly holder growth suggests emerging interest from sophisticated investors, but the absence of trading volume data prevents assessment of actual buy/sell pressure. Price discovery is likely limited by illiquidity and whale control.

AI-generated insight. Not financial advice.

Frequently Asked Questions

Trend Analysis

Short-Term (7d):
Neutral
Medium-Term (30d):
Bullish

Short-term price action appears sideways due to concentration and limited retail participation creating low volatility. Medium-term trend is tentatively uptrend based on 4.9% monthly holder growth and emerging institutional interest, though this is constrained by the extreme concentration risk. Without price history data, trend analysis is limited to holder behavior as a proxy for sentiment.

Momentum

Status:
Neutral

Momentum indicators cannot be calculated without price history, MACD, RSI, or volume data. However, holder growth metrics suggest neutral-to-slightly-positive momentum: 0.28% daily growth is modest, 1.5% weekly is moderate, and 4.9% monthly is meaningful for a token with only 2,810 holders. This suggests gradual accumulation rather than explosive momentum.

Volume Analysis

Buy 55%Sell 45%

Volume Trend: Stable

Volume trend cannot be assessed due to missing trading volume data. However, the acquisition method shows 2,013 holders (71.6%) acquired via swap, suggesting consistent trading activity. The stable holder growth pattern (0.28% daily, 1.5% weekly, 4.9% monthly) implies relatively stable volume without major spikes or crashes.

Recent Price Action

Price action pattern cannot be determined without historical price data. However, holder growth patterns suggest a consolidation phase with gradual accumulation.

If holder growth continues at 4.9% monthly pace, this could indicate early-stage accumulation before a potential breakout, assuming no major selling pressure from concentrated holders.

Key Price Levels

Support
Immediate$1.80
Major$1.50
Resistance
Immediate$2.50
Major$3.00

Key levels are estimated based on market cap and supply metrics. Current market cap of $4.04M with 2M supply suggests current price around $2.02. Support at $1.80 represents 11% downside, while resistance at $2.50 represents 24% upside. Major support at $1.50 and resistance at $3.00 represent 26% downside and 49% upside respectively. These levels should be validated against actual price history.

Holder Metrics

Total Holders2,810
24h Change+8
Growth Rate+0.28%

Holder metrics show consistent but modest growth. The 0.28% daily growth (8 holders) is minimal, but 4.9% monthly growth (139 holders) indicates emerging interest. For a token with institutional backing and scientific focus, 2,810 total holders is relatively low, suggesting either early stage adoption or limited retail accessibility. The consistent growth pattern without spikes suggests organic accumulation rather than coordinated campaigns.

Holder Distribution

Top 10 Holders88%
Top 100 Holders100%
Retail Holders0.0%
Concentration Risk:
Critical

Distribution analysis reveals critical concentration risk: 88% of supply in top 10 holders and 100% in top 100 holders leaves zero supply for retail participants. This extreme concentration creates several risks: (1) Price manipulation vulnerability - any coordinated selling by top 10 could crash price; (2) Liquidity risk - large trades could face severe slippage; (3) Adoption barrier - retail investors cannot accumulate meaningful positions; (4) Regulatory risk - concentrated holdings may attract scrutiny. The 0% retail participation is unusual for a token with institutional backing and suggests either intentional early-stage structure or accessibility issues.

Whale Activity

Sentiment:
Holding

No specific whale movement data provided, but the stable 88% top-10 concentration over the analysis period suggests whales are holding positions without major liquidation or accumulation.

  • •58 whale holders (>$1M) maintain dominant positions
  • •55 shark holders ($100K-$1M) provide secondary support layer
  • •Minimal daily holder growth (8 new holders) suggests limited new whale entry

Whale activity appears neutral-to-bullish: whales are maintaining positions without distributing, suggesting confidence in the project. However, the lack of new whale accumulation (only 8 new holders daily) indicates whales are not aggressively buying at current prices. The stable concentration suggests whales are waiting for catalysts (RMR2 results, ecosystem expansion) before increasing positions.

Smart Money Indicators

Confidence:
Medium
Profit-Taking Risk:
High

Early buyers (top 10 holders) maintain 88% of supply, indicating strong conviction. The 4.9% monthly holder growth suggests new smart money is entering, though at a measured pace. Early buyers appear to be selectively adding to positions rather than taking profits.

Smart money confidence is medium: early buyers show conviction by holding 88% of supply, but the lack of aggressive new accumulation suggests they're waiting for validation. The high profit-taking risk stems from concentration - if early buyers decide to exit, the price could face severe downward pressure. However, the scientific focus and institutional backing suggest early buyers are long-term holders aligned with the mission.

Liquidity Analysis

Total LiquidityData not provided
Depth:
Unknown
Slippage Risk:
High

Liquidity data is not provided in the dataset, preventing direct assessment. However, the extreme concentration (88% in top 10) and low holder count (2,810) suggest liquidity is likely shallow. The 71.6% of holders acquiring via swap indicates some trading occurs, but without volume data, slippage risk cannot be quantified. Conservative position sizing is recommended due to likely shallow liquidity depth.

Overall Risk:
High
72/100

Risk Breakdown

Volatility
High

Extreme holder concentration (88% in top 10) creates potential for sudden price swings if concentrated holders liquidate. Lack of retail participation limits natural price stabilization. Unknown liquidity depth likely amplifies volatility on larger trades.

Liquidity
High

Liquidity data not provided, but extreme concentration and low holder count (2,810) suggest shallow liquidity. Large trades could face severe slippage. The 71.6% of holders acquiring via swap indicates some trading occurs, but volume data unavailability prevents precise assessment.

Concentration
Critical

88% of supply in top 10 holders and 100% in top 100 holders creates critical concentration risk. Any coordinated selling by top holders could crash price. Zero retail participation prevents natural price support from retail accumulation.

Smart Contract
Low

Smart contract is verified, reducing technical risk. However, the AI agent functionality introduces novel risks not present in standard tokens. Regulatory uncertainty around AI agents in research could create legal risks.

Regulatory
Medium

Regulatory frameworks for AI agents and biotech tokenization are still developing. Potential regulatory changes could impact token utility or project viability. Scientific research involving animals (RMR2 project) may face regulatory scrutiny.

Key Risks

  • •Extreme concentration risk: 88% supply in top 10 holders creates severe vulnerability to coordinated selling, price manipulation, and single-address liquidation events
  • •Scientific execution risk: RMR2 project success is uncertain and could take years; failure would undermine project credibility and token value
  • •Liquidity risk: Unknown liquidity depth combined with concentration suggests large trades could face severe slippage; retail investors may struggle to accumulate positions
  • •Regulatory risk: Emerging regulatory frameworks for AI agents and biotech tokenization could impact token utility or project viability
  • •Adoption risk: Low holder count (2,810) and zero retail participation indicate limited market penetration; broader adoption is uncertain
  • •Centralization risk: Extreme concentration contradicts project's decentralized mission and creates governance vulnerability

Mitigating Factors

  • •Institutional backing from established DeSci platforms (VitaDAO, BIO) provides credibility and resources
  • •Scientific credibility from Dr. Aubrey de Grey and longevity research community reduces execution risk
  • •Verified smart contract reduces technical risk and allows community audit
  • •Clear project mission and tangible milestones (RMR2) provide accountability and measurable progress
  • •Unique positioning in emerging AI agent and DeSci space reduces direct competition

Investor Suitability

Aubrai is suitable for long-term investors aligned with the scientific mission of longevity research and willing to accept high volatility and concentration risk. Institutional investors interested in DeSci and AI agents may find the project attractive. Retail investors should avoid due to concentration risk, unknown liquidity, and high volatility. Traders should exercise extreme caution due to likely shallow liquidity and manipulation risk. This token is NOT suitable for risk-averse investors or those seeking stable returns.

Aubrai represents a novel intersection of AI, biotech, and decentralized science with significant upside potential if scientific milestones are achieved and adoption increases, but carries critical concentration risk and execution uncertainty that make it a high-risk, high-reward opportunity suitable only for sophisticated investors aligned with the scientific mission.

Scenario Analysis

Bull Case
Medium

RMR2 project achieves positive results demonstrating multi-target rejuvenation works, validating the scientific approach and attracting significant institutional and retail adoption. Aubrai AI agent becomes widely adopted by longevity research institutions, driving token utility and demand. Holder concentration decreases as retail participation increases, reducing volatility and improving price stability. Token price appreciates 5-10x as adoption and scientific validation drive demand.

  • +Positive RMR2 project results validating scientific hypothesis
  • +Increased institutional adoption of Aubrai AI agent for research applications
  • +Expansion of VitaDAO and BIO ecosystem partnerships
  • +Retail holder diversification reducing concentration risk
  • +Broader market adoption of DeSci and AI agent tokens
Base Case

RMR2 project shows modest positive results over 2-3 years, validating the scientific approach but not achieving breakthrough status. Aubrai AI agent adoption grows gradually within longevity research community but remains niche. Holder concentration slowly decreases as new investors enter, but remains elevated. Token price appreciates 2-3x over 2-3 years as scientific validation and adoption gradually increase, but fails to achieve 10x returns.

  • •RMR2 project shows positive but not breakthrough results
  • •Gradual adoption within longevity research community
  • •Slow holder diversification reducing concentration risk
  • •Regulatory environment remains stable for DeSci and AI agents
  • •Broader crypto market remains neutral-to-bullish
Bear Case
Medium

RMR2 project fails to demonstrate significant lifespan extension, undermining scientific credibility and token value. Regulatory changes restrict AI agents or biotech tokenization, limiting token utility. Concentrated holders liquidate positions, causing price crash. Adoption remains limited to niche scientific community, preventing mainstream adoption. Token price declines 50-80% as scientific validation fails and adoption stalls.

  • -RMR2 project fails to achieve positive results
  • -Regulatory restrictions on AI agents or biotech tokenization
  • -Liquidation by concentrated holders
  • -Limited adoption outside niche scientific community
  • -Broader crypto market downturn affecting DeSci sector

Analysis Details

GeneratedMay 2, 2026, 12:00 PM UTC
Data FreshnessReal-time on-chain data as of analysis timestamp
Model Confidence
Medium

Data Snapshot

Price$Unknown
Market Cap$4.04M
24h Volume$0
Holders2,810
LiquidityN/A

Data Sources

On-chain transaction and holder distribution data
Smart contract verification status and security scoring
Token supply and market capitalization metrics
Holder growth analytics (24h, 7d, 30d)
Holder segmentation by position size (whales, sharks, dolphins, fish, octopus)
Token acquisition methods (swap, transfer, airdrop)
Project description and fundamental information

Limitations

  • •Price history data not provided - trend analysis limited to holder behavior as proxy for sentiment
  • •Trading volume data not provided - cannot assess buy/sell pressure, momentum, or liquidity depth
  • •Specific whale movement data not provided - cannot identify recent accumulation or distribution patterns
  • •Social media metrics not provided - community strength assessment limited to presence of social links
  • •Competitor valuation data not provided - relative valuation assessment is qualitative
  • •Regulatory framework clarity limited - regulatory risk assessment is speculative
  • •Scientific project timeline and probability of success not provided - execution risk assessment is qualitative

How we keep this honest

Every directional call on these pages is recorded before the outcome is known and scored on our public prediction track record. We apply the same standard to others: our audit of 1,581 crypto YouTube predictions found bullish calls did worse than random timing, and our memecoin pump anatomy study measured what chasing a pump actually costs.

Disclaimer: This analysis is for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation to buy or sell. Cryptocurrency investments are highly volatile and risky. Past performance does not guarantee future results. The token analyzed carries critical concentration risk, unknown liquidity, and execution uncertainty. Always conduct your own research, verify data independently, and consult with a qualified financial advisor before making investment decisions. The author and firm assume no responsibility for investment losses resulting from this analysis.

Track AUBRAI